MyMedR

Fulltext Extracellular vesicle-based EGFR genotyping in bronchoalveolar lavage fluid

Liam CK, Liam YS, Wong CK

Transl Lung Cancer Res, 2020 Apr;9(2):168-171.

PMID: 32420055 DOI: 10.21037/tlcr.2020.03.06

Fulltext Impact of clinical features on the efficacy of osimertinib treatment in epidermal growth factor receptor mutant non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors due to T790M mutation

Liam CK, Poh ME, Liam YS

J Thorac Dis, 2019 Sep;11(Suppl 15):S1847-S1851.

PMID: 31632766 DOI: 10.21037/jtd.2019.08.117

Fulltext Accuracy of lung cancer staging in the multidisciplinary team setting

Liam CK, Liam YS, Poh ME, Wong CK

Transl Lung Cancer Res, 2020 Aug;9(4):1654-1666.

PMID: 32953539 DOI: 10.21037/tlcr.2019.11.28

Accurate staging of lung cancer is of utmost importance in determining the stage-appropriate treatment and prognosis. Imaging tests which include contrast-enhanced computed tomography (CT) examination of the chest to include the liver and adrenal glands and 18-fluoro-2 deoxyglucose positron emission tomography (PET)/CT scan facilitate the initial tumor node metastasis (TNM) staging of the disease and provide guidance on the optimal biopsy site and biopsy method. The diagnostic and staging approach should be tailored to the individual patient according to risk, benefit, patient preferences, and available expertise. Diagnosis and staging should preferably be accomplished with a single procedure or the least number of invasive procedures if more than one is needed. Ideally, centers managing lung cancer patients should have a multidisciplinary thoracic oncology board prescribing personalized evidence-based management tailored to each individual patient. Multidisciplinary team (MDT) meetings provide a platform for key experts from various disciplines to contribute specific advice on the management of each individual patient. As assessment of mediastinal lymph node involvement is an important component of lung cancer staging, optimal mediastinal staging can be achieved with a variety of techniques that can be discussed and performed by the various specialists in the MDT. Despite a relative paucity of quality evidence that MDT contributes to improvements in lung cancer survival outcomes, this approach has evolved to become the standard of care in many centers around the world. Thoracic MDT has resulted in more focused and timely investigations for histopathologic diagnosis and disease staging which translate into earlier treatment initiation. Moreover, there is increasing evidence that MDT care facilitates and allows access to investigations that lead to improved accuracy of tumor and nodal staging. However, there is still a paucity of evidence on the accuracy of lung cancer staging in the MDT setting.

Fulltext Molecular testing of metastatic non-small cell lung cancer in the Asia-Pacific region

Liam CK, Stone E, Andarini S, Liam YS, Lam DC, Lee P

Respirology, 2020 07;25(7):685-687.

PMID: 32363718 DOI: 10.1111/resp.13833

Fulltext Common driver mutations and programmed death-ligand 1 expression in advanced non-small cell lung cancer in smokers and never smokers

Liam CK, Yew CY, Pang YK, Wong CK, Poh ME, Tan JL, et al.

BMC Cancer, 2023 Jul 14;23(1):659.

PMID: 37452277 DOI: 10.1186/s12885-023-11156-y

BACKGROUND: In non-small cell lung cancer (NSCLC), there may be a relationship between programmed death-ligand 1 (PD-L1) expression, driver mutations and cigarette smoking.

METHODS: In this single-center retrospective study, the relationship between common driver mutations (EGFR mutation and ALK rearrangement) and PD-L1 expression in advanced NSCLC according to the patients' smoking history was examined. Light, moderate and heavy smokers had smoked

Displaying all 5 publications